Company profile
Eton Pharmaceuticals, Inc.
NASDAQ: ETON · Healthcare · Drug Manufacturers - Specialty & Generic
#375 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
60CFH 70DQ 49GM 57SS 56
v0.1 · 65/100 weight · provisional
↑ Altman-Z, revenue growth (YoY) · ↓ growth stability, listing tenure
Methodology →Revenue TTM
$86.9M
Rev growth YoY (TTM)
+79.9%
Net income (FY)
-$4.6M
Employees
44
as of 2026-08-10
Market cap
$1.2B
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$80.0M$80.0M2025
Net income-$4.6M-$4.6M2025
Operating income-$844.0k-$844.0k2025
Total assets$92.1M$92.1M2025
Liabilities$66.0M$66.0M2025
Equity$26.2M$26.2M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product Sales and Royalties96%
License4%
By geography
Not disclosed.
The read
What is Eton Pharmaceuticals, Inc.’s revenue?
Eton Pharmaceuticals, Inc. booked $80.0M in FY2025 revenue, growing 105% year over year — faster than most Healthcare companies we track, at a -5.8% net margin.
Peers · Healthcare
MeiraGTx Holdings plc48DDecibel Cannabis Company Inc.62CTELA Bio, Inc.47DVitalhub Corp.77B+Sight Sciences, Inc.53DCannara Biotech Inc.77B+Neighbors
Lake →Key facts
CEOSean E. Brynjelsen
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersDeer Park, IL
ExchangeNASDAQ: ETON
Employees44
IPO date2018-11-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.